<!DOCTYPE html>
<!--
==============================================================================
           "GitHub HTML5 Pandoc Template" v2.1 — by Tristano Ajmone           
==============================================================================
Copyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:

- https://github.com/tajmone/pandoc-goodies

The CSS in this template reuses source code taken from the following projects:

- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):
  https://github.com/sindresorhus/github-markdown-css

- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):
  http://primercss.io/

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
The MIT License 

Copyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)
Copyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)
Copyright (c) 2017 GitHub Inc.

"GitHub Pandoc HTML5 Template" is Copyright (c) Tristano Ajmone, 2017, released
under the MIT License (MIT); it contains readaptations of substantial portions
of the following third party softwares:

(1) "GitHub Markdown CSS", Copyright (c) Sindre Sorhus, MIT License (MIT).
(2) "Primer CSS", Copyright (c) 2016 GitHub Inc., MIT License (MIT).

Permission is hereby granted, free of charge, to any person obtaining a copy
of this software and associated documentation files (the "Software"), to deal
in the Software without restriction, including without limitation the rights
to use, copy, modify, merge, publish, distribute, sublicense, and/or sell
copies of the Software, and to permit persons to whom the Software is
furnished to do so, subject to the following conditions:

The above copyright notice and this permission notice shall be included in all
copies or substantial portions of the Software.

THE SOFTWARE IS PROVIDED "AS IS", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR
IMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,
FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE
AUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER
LIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,
OUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE
SOFTWARE.
==============================================================================-->
<html>
<head>
  <meta charset="utf-8" />
  <meta name="generator" content="pandoc" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes" />
  <title>Rheumatic heart disease MeG-CLS-065</title>
  <style type="text/css">
@charset "UTF-8";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,"Segoe UI",Helvetica,Arial,sans-serif,"Apple Color Emoji","Segoe UI Emoji","Segoe UI Symbol";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:""}.markdown-body hr::after{display:table;clear:both;content:""}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,"Liberation Mono",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,"Liberation Mono",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:" "}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,"Liberation Mono",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:""}.markdown-body::after{display:table;clear:both;content:""}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}
  </style>
  <style type="text/css">code{white-space: pre;}</style>
  <!--[if lt IE 9]>
    <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js"></script>
  <![endif]-->
</head>
<body>
<article class="markdown-body">
<h1 id="rheumatic-heart-disease">Rheumatic heart disease</h1>
<h2 id="executive-summary"><em>Executive summary</em></h2>
<h2 id="introduction">Introduction</h2>
<p>Rheumatic heart disease (RHD) is a serious complication of rheumatic fever. It refers to the chronic heart valve damage that can develop years after single or repeated episodes of acute rheumatic fever (ARF). Acute rheumatic fever is an inflammatory autoimmune disease which occurs following inadequately treated infection with Group A Streptococcus (GAS). Repeated episodes of ARF can lead to inflammation of the heart either on the surface of the heart (pericarditis), within the heart (endocarditis) leading to accumulative damage to one or more of the four heart valves (endocarditis) or involving the heart muscle itself (myocarditis). Untreated RHD can lead to heart failure, stroke, arrhythmia and complications in pregnancy.</p>
<p>RHD is a disease of poverty, associated with overcrowding and poor living conditions, as well as lack of access to health care and services.</p>
<p>Group A streptococcal infection, acute rheumatic fever and rheumatic heart disease are preventable with improved housing and living conditions, and early antibiotic treatment.</p>
<h2 id="target-users">Target users</h2>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Doctors</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Nurses</p>
</div></li>
</ul>
<h2 id="target-area-of-use">Target area of use </h2>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Outpatient department</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Ward</p>
</div></li>
</ul>
<h2 id="key-areas-of-focus-new-additions-changes">Key areas of focus / New additions / Changes </h2>
<p>This guidelines describes the initial diagnosis and management of rheumatic heart disease. Advanced rheumatic heart disease requires surgical treatment which is delivered through a partnership with the UK charity Chain of Hope. Management of these children is shared with overseas paediatric cardiologists who will advise on more complex problems.</p>
<h2 id="limitations">Limitations</h2>
<p>Access to surgery is limited and many children must be managed medically.</p>
<h2 id="presenting-symptoms-and-signs">Presenting symptoms and signs</h2>
<p>The most common forms of RHD include mitral valve disease (mitral stenosis, mitral regurgitation), aortic valve disease (aortic stenosis, aortic regurgitation) and tricuspid regurgitation. Atrial fibrillation is often associated with mitral stenosis.</p>
<p>Clinical features of RHD vary depending on which heart valves are affected and how severely. Early in the onset of disease, cases may be asymptomatic for many years. As valvular disease progresses, cases will have symptoms of some degree of heart failure, ranging from mild to severe exertional dyspnoea, fatigue, peripheral oedema and palpitations. The severity of RHD increases with repeated episodes of ARF.</p>
<p>Complications of RHD include heart failure, stroke, arrhythmias, infective endocarditis and complications during pregnancy. Heart failure is the major cause of disability and death from RHD. Infective endocarditis is more likely to occur when there is damage to the heart valves and is a serious illness requiring hospitalisation and intravenous antibiotics, which is also associated with a significant mortality and morbidity burden.</p>
<p>Other symptoms due to rheumatic heart disease are:</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Chest pain.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Heart palpitations.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Shortness of breath especially with physical exertion.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Swollen ankles, legs, wrists, and stomach.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Excessive fatigue.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Thumping sensation in chest.</p>
</div></li>
</ul>
<h2 id="examination-findings">Examination findings</h2>
<p>These vary with the severity of valve calcification, the severity of stenosis, and left ventricular (LV) function.</p>
<p>With mild disease, the apex beat is brisk and hyper dynamic. The S<sub>1</sub> is usually soft, and a widely split S<sub>2</sub> is common. A diastolic rumble and S<sub>3</sub> may be present even if there is no LV dysfunction.</p>
<p>With severe mitral regurgitation (MR), the apex may be enlarged and displaced laterally. The systolic murmur of MR varies according to its cause. It is usually heard best at the apex in the left lateral decubitus position. With severe degenerative MR, the murmur is holosystolic, radiating into the axilla. Early systolic murmurs are typical of acute MR. Late systolic murmurs are typical of mitral valve prolapse or papillary muscle dysfunction.</p>
<p>Signs of pulmonary hypertension, such as a loud P<sub>2</sub>, represent advanced disease.</p>
<h2 id="differential-diagnosis">Differential diagnosis</h2>
<p>The main alternative diagnosis in children is infectious endocarditis or congenital heart disease. In adults, valvular heart disease might be due to degenerative changes.</p>
<h2 id="investigations">Investigations</h2>
<ul>
<li><div data-custom-style="List Paragraph">
<p><strong>CXR</strong></p>
</div>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Heart failure: enlarged heart, congested pulmonary vasculature. If more severe: enlarged right atrium and right ventricle.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Chronic MR: cardiomegaly (LV and LA enlargement).</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Acute MR or progressive LV failure: Kerley B lines and interstitial oedema.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Pulmonary hypertension: right-sided chamber enlargement.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Severe mitral stenosis: left atrial enlargement.</p>
</div></li>
</ul></li>
<li><div data-custom-style="List Paragraph">
<p><strong>ECG</strong> – Looking for LV hypertrophy, LA enlargement, conduction abnormality (left and right bundle branch block), altered axis, atrial fibrillation.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p><strong>ECHO</strong> – Essential to confirm the diagnosis and grade the severity of disease.</p>
</div></li>
</ul>
<p>Other investigations are not available in the Gambia.</p>
<h2 id="management">Management </h2>
<p>There are 2 goals in treating RHD:</p>
<ol type="1">
<li><div data-custom-style="List Paragraph">
<p>Prevention of further damage to the heart valves.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Treatment of heart failure.</p>
</div></li>
</ol>
<h3 id="prevention-of-further-damage-to-the-valves">Prevention of further damage to the valves</h3>
<p>Primary prevention involves the use of antibiotics to treat GAS throat infections.</p>
<p>Secondary prevention of ARF: once a person has had ARF, it is important to prevent future episodes, this is best provided by monthly IM injections of Benzathine penicillin at a dose of 1.2 MU. This is increased to 3 weekly if the patient is at especially high risk. It should be continued until 10 years after the last episode of ARF or the age of 21 years. This treatment reduces the number of ARF episodes and should be offered to all patients with rheumatic carditis. For persons with established rheumatic heart disease, secondary prevention with continuous antibiotics should be continued for longer periods – even for life. It is also continued even after valve surgery.</p>
<p>Penicillin V has been used in place of Benzathine penicillin. Patients prefer it, but there is concern that it is less effective because it depends on them taking medication every day. There is no evidence to support its use.</p>
<h3 id="treatment-of-heart-failure">Treatment of heart failure</h3>
<p><span class="underline">Medical treatment</span></p>
<p><strong>ACE inhibitors</strong> block the formation of angiotensin II, this medication lowers blood pressure and reduces sodium retention in people who have heart failure. They are relatively contraindicated in patients with mitral or aortic stenosis.</p>
<p>Use enalapril 100 micrograms/kg OD initially. The dose can be increased up to 1 mg/kg OD. The maximum dose is 10 mg OD. Ramipril or captopril can be substituted according to availability.</p>
<p><strong>Beta blockers</strong> block the effect of adrenaline on the heart to reduce excess stress on the failing heart. These medications are most commonly used for dilated cardiomyopathy.</p>
<p>Use bisoprolol 1.25 mg OD in older children. Use in younger children only on the advice of a cardiologist.</p>
<p><strong>Diuretics</strong> stimulate the body to lose water by acting on the kidneys. This effect decreases fluid retention and edema and provides symptomatic relief to the patient.</p>
<p>Start with furosemide 0.5 mg/kg OD. The dose can be increased as high as 12 mg/kg, but it is unusual to need doses higher that 2 mg/kg OD.</p>
<p>Add spironolactone 1 mg/kg OD. The dose can be increased up to 9 mg/kg OD, but usually lower doses are needed in heart failure.</p>
<p><span class="underline">Surgical treatment</span></p>
<p>Patients with significant heart failure should be considered for valve repair or replacement surgery. In an ideal world, even asymptomatic patients should be considered for this in order to prevent significant heart damage.</p>
<p>Patients are often very young when operated and, therefore, are given mechanical valves if they need replacement surgery, as they last longer. However, they then require warfarin treatment. Girls offered mechanical valves should be counselled about the risks of being pregnant on warfarin treatment and about the option of using low-molecular weight heparin through the pregnancy. The target INR is usually 2.5-3.5.</p>
<h2 id="key-issues-for-nursing-care">Key Issues for Nursing care</h2>
<h2 id="make-sure-patients-and-their-caregivers-understand-why-they-have-been-given-penicillin-prophylaxis-and-how-important-it-is-to-prevent-further-episodes-of-arf.">Make sure patients and their caregivers understand why they have been given penicillin prophylaxis and how important it is to prevent further episodes of ARF.</h2>
<h2 id="references">References</h2>
<p>Queensland Health Guidelines</p>
<p>Maganti, K., Rigolin,V.H., Sarano, M.E.,MD, and Bonow, R.O. Valvular Heart Disease: Diagnosis and Management. Mayo Clin Proc. 2010. 85(5): 483–500.</p>
<table>
<thead>
<tr class="header">
<th><strong>Written by:</strong></th>
<th>Name: Baderinwa Abatan</th>
<th>Date: 13 March 2019</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Reviewed by:</strong></td>
<td>Name: Karen Forrest</td>
<td>Date: 07 May 2019</td>
</tr>
<tr class="even">
<td><strong>Version:</strong></td>
<td><strong>Change history:</strong></td>
<td><strong>Review due date:</strong></td>
</tr>
<tr class="odd">
<td>1.0</td>
<td>New document</td>
<td>31 May 2021</td>
</tr>
<tr class="even">
<td>Review Comments (<em>if applicable)</em></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
</article>
</body>
</html>
